Evolus (NASDAQ:EOLS), a global performance beauty company dedicated to building a differentiated aesthetic portfolio, announced preliminary, unaudited net revenue results for the fourth quarter and full year ended December 31, 2025, along with updated forward-looking guidance.
Amazon Pharmacy (NASDAQ:AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, now offers Novo Nordisk’s Wegovy® pill, the first and only FDA-approved oral GLP-1 for weight management, through many insurance plans as well as a transparent cash-pay option.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it has entered into an exclusive global license agreement with Pfizer (NYSE:PFE) for ervogastat (formerly PF-06865571), an oral diacylglycerol acyltransferase 2 (DGAT-2) inhibitor currently in Phase 2 development, as well as rights to two additional early-stage metabolic dysfunction-associated steatohepatitis (MASH) assets.
Boston-based Rhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, announced preliminary, unaudited net product revenues for its flagship therapy IMCIVREE (setmelanotide) for the fourth quarter and full year ended December 31, 2025.
Beijing-based Global Mofy Metaverse Limited (NASDAQ:GMM), a technology platform specializing in AI-driven virtual content creation for the metaverse and entertainment industries, reported record financial results for its fiscal year ended September 30, 2025.
Delcath Systems (NASDAQ:DCTH), an interventional oncology company specializing in treatments for primary and metastatic liver cancers, announced preliminary unaudited financial results and business updates for the fourth quarter and full year ended December 31, 2025.
Cartesian Therapeutics (NASDAQ:RNAC) provided an update on its Descartes-08 program, a first-in-class autologous mRNA-engineered CAR-T cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases, and outlined key 2026 priorities.
Schrödinger (NASDAQ:SGDR) announced a strategic collaboration with Eli Lilly and Company (NYSE:LLY) on Friday to integrate Lilly’s high-powered TuneLab™ AI platform directly into Schrödinger’s flagship enterprise software, LiveDesign.
Palvella Therapeutics (NASDAQ:PVLA) issued a comprehensive 2026 corporate update detailing significant progress across its late-stage QTORIN platform, which leverages a proprietary topical rapamycin formulation for the treatment of rare dermatological and vascular conditions.
